XENE May 2024 45.000 call
- GlobeNewswire
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nas
- GlobeNewswire
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation Details:Date:Wednesday, May 15, 2024Time:3:40 pm Pacific Time (6:40 pm Eastern Time)Webcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry A
- GlobeNewswire
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY. Fireside Chat Presentation Details: Date:Tuesday, May 14, 2024Time:3:35 pm Eastern TimeWebcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry Aulin, Chief Fin
